Drug resistance, both intrinsic and acquired, remains a major clinical obstacle in chemotherapy of tumours in man. Acquisition of resistance to multiple anticancer agents such as Vinca alkaloids, anthracyclines and epipodophyllotoxins is often correlated with enhanced expression of gpl70, a membranous glycoprotein with molecular weight of 170,000 coded by the mdr-l gene: gpl70 catalyses the outward efflux of drugs, resulting in reduced cellular accumulation of the chemotherapeutic agents (Pastan & Gottesman, 1987; Beck, 1987; Bradley et al., 1988) . Gpl70 or its structural mdr-l gene has been detected in tumour cells from patients with ovarian cancer, soft tissue sarcoma, acute leukaemia, multiple myeloma, nonHodgkin's lymphoma, and several other human tumours (Bell et al., 1985; Gerlach et al., 1987; Ma et al., 1987; Fojo et al., 1987; Dalton et al., 1989; Nakagawara et al., 1990) . Goldstein et al. (1989) investigated the mdr-J mRNA levels in many types of human cancers, and proposed that the expression of mdr-J was associated with several intrinsically resistant cancers. They also observed the increased level of the mdr-J gene in certain cancers after chemotherapy, suggesting a correlation of the expression of the mdr-J gene with acquired drug resistance.
To find a way to overcome multidrug resistance (MDR), a combination chemotherapy of anticancer agents and other agents which may block the drug efflux in MDR cells has been tested on drug-resistant tumour cells (Tsuruo et al., 1981; Yamaguchi et al., 1986; Nakagawa et al., 1986; Shiraishi et al., 1987) . Most of the second agents that can reverse MDR inhibit the photoaffinity labeling of gpl70 by azidopine or a vindesine analog (Cornwell et al., 1986; Safa & Felsted, 1987; Akiyama et al., 1988) ; and a polyprenoid with potent MDR-reversing activity binds specifically to the gpl70 (Akiyama et al., 1989) . One can further anticipate that potent MDR-reversing agents with few side effects and low calcium channel blocking activity may be useful second agents in practical cancer chemotherapy. From this standpoint, dihydropyridine derivatives with few side effects have been screened to see if they could overcome MDR. Some dihydropyridines demonstrated low calcium channel blocking activity, but potent MDR-reversing activity in vivo (Shinoda et al., 1989) as well as in vitro (Kamiwatari et al., 1989; Yoshinari et al., 1989) . In our laboratory, among the many dihydropyridines tested, lipophilic 1,4-dihydropyridines were found to effectively overcome MDR in vitro (Nogae et al., 1989) . We had further screened 57 newly synthesised 1,4-dihydropyridine derivatives for their ability to overcome vincristine (VCR)-resistance in mice with P388 leukaemia resistant to VCR (P388/VCR) (Kiue et al., 1990a) . Representative 1,4-dihydropyridine derivatives, NK-250 and NK252, which have low calcium channel blocking activity and very high affinity for gpl70, could potentiate the antitumour activity of VCR in mice inoculated i.p. with drug-resistant tumour cells (Kiue et al., 1990a) . In our most recent study, the p.o. administration of NK-250 and NK-252 was shown to potentiate the antitumour activity of MDR-related anticancer drugs in mice with drug-sensitive and drug-resistant tumour cells (Kiue et al., 1990b) . In this study, we examined whether (1) NK-compounds could potentiate the action of another antitumour agent, etoposide, a semisynthetic derivative of epipodophyllotoxin, and (2) the effect of NK-compounds on the anticancer activity of etoposide when the tumour cells and antitumour drugs were administered by various routes. We then examined the antitumour effects of a combination of NK-250 and etoposide on drug-resistant P388/VCR-mice. Etoposide alone administered i.p. increased in a dose-dependent manner the life-span of mice inoculated i.p. with the drug-resistant P388/VCR leukaemia (Table III) Combined effects of etoposide and NK-252 on P388/S-and P388/ VCR-mice We examined the antitumour effects of the combination of etoposide and another dihydropyridine derivative, NK-252, against drug-sensitive and drug-resistant leukaemia-bearing mice. The combination therapy of etoposide with NK-252 administered p.o. significantly increased the life-span of mice inoculated i.p. with P388/S compared with the corresponding therapeutic effects with etoposide alone, but the prolonging effect was less than with NK-250 (Table IV) . When etoposide was combined with NK-252, some mice survived longer than 60 days in the P388/S-mice. On the other hand, combination therapy with etoposide and NK-252 significantly increased the life-span of mice inoculated i.p. with P388/VCR compared with the corresponding survival time with etoposide alone, but the prolonging effect was less than with NK-250.
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Therapeutic experiments with animal models bearing drugsensitive and drug-resistant tumours are often employed to determine the effectiveness of drug-resistance reversal agents. (Kiue et al., 1990b) . Consistent with many other MDR-reversal agents that show high affinity to gpl70 (Cornwell et al., 1986; Safa & Felsted, 1987; Akiyama et al., 1988 and , NK-250 and NK252 also show very high affinity to the gpl70 (Kiue et al., 1990a and 1990b) . Kamiwatari et al. (1989) and Yoshinari et al. (1989) have reported that other dihydropyridine derivatives reversed MDR almost completely in MDR cells in culture, and effective dihydropyridines showed very high affinity to gpl7O. A relevant paper by Shinoda et al. (1989) reported that combination treatment of VCR administered i.p. VCR with a 1,4-dihydropyridine derivative, AHC-52, administered i.p. in mice inoculated i.p. with drug-sensitive P388/S leukaemia resulted in survival of mice for longer than 60 days. The chemical structures of these dihydropyridine derivatives, however, are very different from those of NK-compounds.
MDR cells are often cross-resistant to etoposide and its related epipodophyllotoxin or teniposide, while the resistance levels to etoposide and teniposide are relatively low in comparison with that to anthracyclines or Vinca alkaloids (Beck, 1987; Danks et al., 1987) . Gpl70 is apparently expressed in P388/VCR cells, but not in P388/S cells (Kiue et al., 1990b) . Mice with P388/VCR leukaemia are about 3-times more resistant to the etoposide treatment than mice with P388/S leukaemia (see Figure 3) , suggesting that the selected drug-resistance model in our present study is one with a very low degree of resistance. Combination with NK-250 or NK-252 potentiates the antitumour activity of etoposide in both the drug-sensitive P388/S and drug-resistant P388/VCR mice. Etoposide-resistance in tumour cells might be partly associated with decreased drug accumulation, presumably by gp170-mediated enhanced drug efflux, a process shared by several anticancer agents including Vinca alkaloids, anthracyclines and actinomycin-D. his colleagues (1984 and 1985a) have reported that verapamil, a potent MDR-reversing agent, potentiates etoposide as well as VCR and other anticancer agents in drug-sensitive leukaemia cells in culture. As a plausible mechanism for the potentiation of etoposide, they have demonstrated verapamil-induced augmentation of etoposide accumulation in the leukaemia cells in culture (Yalowich & Ross, 1985b) . Slater et al. (1986) have also reported a relevant paper that verapamil can potentiate etoposide against drug-sensitive and drug-resistant leukaemia in vitro as well as in vivo. It remains unknown what mechanisms may be involved in the potentiation of etoposide by verapamil. Our recent study also demonstrated that intracellular accumulation of [3H]etoposide was enhanced by NK-250 or NK-252 in both drug-sensitive and their MDR counterpart cell lines in culture (Watanabe et al., 1990) , but neither NK-compounds inhibited the efflux of etoposide (unpublished data). Inhibition of gp170-mediated drug efflux thus appears to be only partially, if at all involved in NK-250 or NK-252-induced potentiation of etoposide against drug-sensitive tumour cells (Watanabe et al., 1990) . The increased bio-availability of etoposide by dihydropyridine derivative might be mainly due to enhanced transport of etoposide in tumour cells. Although the exact mechanims for the dihydropyridine-induced potentiation of etoposide remain unclear, combination therapy of etoposide with dihydropyridines such as NK-250 or NK-252 should be further evaluated.
